Evidence map›Paper›PMID 40476034›Full record

ArticleOpen forum infectious diseases2025

Early Virologic Success on Antiretroviral Therapy Among Individuals With Breakthrough HIV Acquisition on Long-Acting Cabotegravir Pre-exposure Prophylaxis.

Urvi M Parikh, Monica Gandhi, Jessica Altamirano, Hussein Safa, Aniruddha Hazra, Lisa Georgetti Gomez, Prerak Shukla, Trevor Hedberg, Amy L Heaps, Elias K Halvas and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Urvi M ParikhUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Monica GandhiUniversity of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-6674-5388
Jessica AltamiranoCAN Community Health, Tampa, Florida, USA.ORCID https://orcid.org/0009-0005-4344-2399
Hussein SafaJefferson Health, Philadelphia, Pennsylvania, USA.
Aniruddha HazraUniversity of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-8557-4465
Lisa Georgetti GomezUniversity of California, San Francisco, San Francisco, California, USA.
Prerak ShuklaCAN Community Health, Tampa, Florida, USA.
Trevor HedbergHoward Brown Health, Chicago, Illinois, USA.
Amy L HeapsUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-4410-4007
Elias K HalvasUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Karen KunczeUniversity of California, San Francisco, San Francisco, California, USA.
Hideaki OkochiUniversity of California, San Francisco, San Francisco, California, USA.
Charles WalworthMonogram Biosciences/Labcorp of America® Holdings, Burlington, North Carolina, USA.
Amy ConroyUniversity of California, San Francisco, San Francisco, California, USA.
Chris BositisUniversity of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0009-0002-0469-6634
Carolyn ChuUniversity of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0780-1081
John W MellorsUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-3737-9742
Catherine A KossUniversity of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-7297-175X

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
ACTION: Study of ACuTe Infections On Novel HIV Prevention ModalitiesR01AI167753 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Catherine Anne Stimets Koss, Urvi M. Parikh · 2022 to 2026
$3.9M
NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI167753
6 · The paper itself

Abstract

HIV-1 breakthrough on long-acting cabotegravir (CAB-LA) for HIV prevention is rare but could impact viral suppression on integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART). We report the first study of ART outcomes following CAB-LA breakthrough during routine clinical care. Three individuals acquired HIV-1 on CAB-LA despite on-time injections; 2 had low-frequency major INSTI resistance mutations. All started darunavir-based ART; 1 subsequently switched to bictegravir-based ART. All maintained plasma HIV-1 RNA <50 copies/mL through ≥5 months post-ART initiation, providing early evidence of virologic success with standard ART regimens and paving the way for longer-term studies on optimal ART after CAB-LA breakthrough.

Indexed as

antiretroviral therapy (ART)HIV drug resistance (HIVDR)integrase strand transfer inhibitors (INSTIs)long-acting cabotegravir (CAB-LA)pre-exposure prophylaxis (PrEP)

Identifiers

PMID40476034
PMCPMC12138330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.